单细胞多基因表征结直肠瘤,相邻的健康组织和匹配的 (瘤) 器官识别CRC独特的特征
Zhijun Yu1,2,3, Merel Derksen4, Brigit M Te Pas1
1Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
International journal of cancer
|August 23, 2025
概括
这项研究揭示了结肠直肠癌 (CRC) 如何在患者衍生器官上发展. 瘤器官捕获CRC的独特分子特征和突变,为癌症研究提供了一个可靠的模型.
科学领域:
- 癌症学
- 基因组学
- 分子生物学
背景情况:
- 结肠直肠癌 (CRC) 涉及到结肠中的遗传突变和异常细胞生长.
- 了解CRC进展的分子基础对于有效治疗至关重要.
研究的目的:
- 通过使用单核多组学来研究结直肠癌的分子格局.
- 用于癌症建模,将原始瘤组织与患者衍生器官 (PDO) 进行比较.
主要方法:
- 对超过10万个核进行了单核RNA测序 (snRNA-seq) 和单核ATAC测序 (snATAC-seq).
- 分析包括初级结直肠组织,并匹配正常和瘤PDO.
- 使用推断的细胞相互作用分析.
主要成果:
- 正常的PDO (N-PDO) 反映了结肠直肠密室的细胞性和分化.
- 瘤PDO (T-PDO) 呈现出患者特异性,保持类似干细胞的状态.
- T-PDO保留了原始瘤突变并获得了新的突变;活性蛋白信号传递与瘤微环境相互作用有关.
结论:
- 在研究结肠直肠癌的分子特征方面, PDO 是一个可靠的模型.
- 这项研究提供了关于CRC正常到恶性表皮细胞转变的见解.
- 这项研究强调了PDO对于捕捉保存和患者特有的CRC特征的有用性.
更多相关视频
12:41Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
5.0K
08:42Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
Published on: June 27, 2025
550
相关概念视频
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...